Gupta Kalpana, Shukla Meenakshi, Cowland Jack B, Malemud Charles J, Haqqi Tariq M
Case Western Reserve University, and University Hospitals of Cleveland, Cleveland, Ohio 44106, USA.
Arthritis Rheum. 2007 Oct;56(10):3326-35. doi: 10.1002/art.22879.
Expression of matrix metalloproteinase 9 (MMP-9) is up-regulated in osteoarthritis (OA) and usually presents as multiple bands when synovial fluid (SF) from OA patients is analyzed by zymography. Among these bands is an approximately 125-130-kd band for high molecular weight (HMW) gelatinase, which has not been characterized. This study was undertaken to characterize the HMW MMP activity in OA SF.
MMP activity in OA SF was determined by gelatin zymography. Recombinant MMPs were used to identify MMP activity on the zymogram. Western immunoblotting, immunoprecipitation, and immunodepletion analyses were performed using antibodies specific for human MMP-9 and human neutrophil gelatinase-associated lipocalin (NGAL). Human cartilage matrix degradation was determined by dimethylmethylene blue assay.
Zymographic analysis showed that the HMW gelatinase in OA SF comigrated with a purified NGAL-MMP-9 complex. Results of Western immunoblotting showed that the HMW gelatinase was also recognized by antibodies specific for human NGAL or human MMP-9. These same antibodies also immunoprecipitated the HMW gelatinase activity from OA SF. The NGAL-MMP-9 complex was reconstituted in vitro in gelatinase buffer. In the presence of NGAL, MMP-9 activity was stabilized; in the absence of NGAL, rapid loss of MMP-9 activity occurred. MMP-9-mediated release of cartilage matrix proteoglycans was significantly higher in the presence of NGAL (P < 0.05).
Our findings demonstrate that the HMW gelatinase activity in OA SF represents a complex of NGAL and MMP-9. The ability of NGAL to protect MMP-9 activity is relevant to cartilage matrix degradation in OA and may represent an important mechanism by which NGAL may contribute to the loss of cartilage matrix proteins in OA.
基质金属蛋白酶9(MMP - 9)在骨关节炎(OA)中表达上调,当对OA患者的滑液(SF)进行酶谱分析时,通常呈现多条条带。在这些条带中,有一条大约125 - 130 kDa的条带代表高分子量(HMW)明胶酶,其特征尚未明确。本研究旨在明确OA滑液中HMW MMP的活性特征。
通过明胶酶谱法测定OA滑液中的MMP活性。使用重组MMP来鉴定酶谱上的MMP活性。采用针对人MMP - 9和人中性粒细胞明胶酶相关脂质运载蛋白(NGAL)的特异性抗体进行Western免疫印迹、免疫沉淀和免疫去除分析。通过二甲基亚甲基蓝测定法确定人软骨基质的降解情况。
酶谱分析显示,OA滑液中的HMW明胶酶与纯化的NGAL - MMP - 9复合物迁移率相同。Western免疫印迹结果表明,HMW明胶酶也能被针对人NGAL或人MMP - 9的特异性抗体识别。这些相同的抗体也能从OA滑液中免疫沉淀HMW明胶酶活性。在明胶酶缓冲液中体外重组了NGAL - MMP - 9复合物。在有NGAL存在时,MMP - 9活性稳定;在没有NGAL时,MMP - 9活性迅速丧失。在有NGAL存在时,MMP - 9介导的软骨基质蛋白聚糖释放显著更高(P < 0.05)。
我们的研究结果表明,OA滑液中的HMW明胶酶活性代表NGAL和MMP - 9的复合物。NGAL保护MMP - 9活性的能力与OA中的软骨基质降解相关,可能代表NGAL导致OA中软骨基质蛋白丢失的重要机制。